Data Sheet 1_Modeling rebound bone loss following denosumab discontinuation and sequential

A 3.3 MB research document by Vagelis Rinotas, uploaded to figshare in March 2026, details a preclinical study on osteoporosis treatment discontinuation. The work uses a transgenic mouse model expressing human RANKL to investigate the severe bone loss rebound after stopping denosumab therapy. Results characterize skeletal changes via microCT, histomorphometry, serum markers, and gene expression, and evaluate the protective effects of sequential zoledronate treatment.

Use Cases

• Modeling the rebound bone loss phenomenon based on microCT and histomorphometric data mentioned in the description.
• Analyzing the relationship between bone turnover markers and marrow adiposity changes following drug discontinuation.
• Evaluating the efficacy of sequential antiresorptive therapies (denosumab followed by zoledronate) in preventing bone loss.
• Studying gene expression patterns in bone tissue related to RANKL inhibition and withdrawal.

Strengths

• Document is under a permissive CC-BY-4.0 license, facilitating reuse.
• Study design includes four distinct experimental groups and a follow-up phase, suggesting structured comparative data.
• Analysis employs multiple characterization methods: microCT, histomorphometry, serum BTMs, and gene expression.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.
• The primary data format is a DOCX file, which may require extraction or conversion for computational use.

Provenance

Source

Vagelis Rinotas via figshare.

Collection Method

Experimental data from a preclinical study using transgenic TgRANKL osteoporotic mice.

Time Range

null

Freshness

Last updated 2026-03-18 07:46:36; freshness should be verified.

Geography

null